No patients developed regional recurrence; however, four patients developed distant recurrence, six patients developed breast cancer in the opposite breast, three patients developed new non-breast primary tumors, and eight patients died (including one death related to breast cancer).
“This study provides important information for clinicians to discuss with patients who have two or three foci of breast cancer in one breast, as it may allow more patients to consider breast-conserving therapy as an option,” said Boughey. “Lumpectomy with radiation therapy is often preferred to mastectomy as it is a smaller operation with quicker recovery, resulting in better patient satisfaction and cosmetic outcomes.”
Ad Statistics
Times Displayed: 31443
Times Visited: 833 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
She added that the results from the trial also suggest that patients who are diagnosed with two or more malignant lesions in the breast and are considering breast-conserving therapy may benefit from breast MRI.
A limitation of the study was its single-arm design. “While a randomized trial design would have provided stronger data, we felt that accrual to such a design would be problematic as many patients and surgeons would not be willing to randomize,” noted Boughey.
The study was supported by the National Institutes of Health. Boughey has received funding for other studies from Eli Lilly and Company, Symbiosis Pharma, CairnSurgical, UpToDate, and PeerView.
Back to HCB News
